To assess whether cblb-deficiency in BMDCs would increase their ability to infiltrate and reject tumors, fully immune-competent C57BL/6 wildtype mice were subcutaneously injected with B16-OVA melanoma cells and vaccinated with semi-matured SIINFEKL-loaded BMDCs from wildtype and cblb−/− donors on day five. This evidence concerns the gene CBLB and melanoma.